title: Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function.
abstract: Two double-blind, randomized, placebo-controlled, parallel group safety and efficacy studies included evaluation of the hypothalamic-pituitary-adrenal (HPA)-axis effects of concurrent treatment with intranasal and orally inhaled fluticasone propionate (FP). In the first study, patients with asthma who were > or =12 years of age were assigned randomly to receive twice-daily doses (either 88 or 220 microg) of orally inhaled FP delivered from a metered-dose inhaler (MDI). In the second study, patients were assigned randomly to receive either orally inhaled FP 250 microg or orally inhaled FP 250 microg/salmeterol 50 microg delivered via the Diskus device. In both studies, patients with rhinitis were allowed to continue the use of intranasal FP at their usual dosing. Treatment periods were 26 weeks and 12 weeks for the MDI and Diskus studies, respectively. HPA-axis effects were assessed using response to short cosyntropin stimulation testing. The number and percentage of patients with an abnormal cortisol response, defined as a morning plasma cortisol of <5 microg/dL, a poststimulation peak of <18 microg/dL, or a poststimulation rise of <7 microg/dL, were summarized in two subgroups: patients who used intranasal FP and those who did not. The concurrent administration of intranasal FP and orally inhaled FP via an MDI or Diskus or via Diskus with salmeterol was not associated with HPA-axis effects compared with orally inhaled FP alone. The results of these two studies suggest that concurrent use of intranasal FP with orally inhaled FP administered via MDI or Diskus for treatment of comorbid rhinitis and asthma does not increase the risk of HPA-axis abnormalities.
authors.affiliation: Lafayette Allergy and Asthma Clinic, Lafayette, Indiana 47905, USA.
authors.forename: Ketan K
authors.initials: KK
authors.lastname: Sheth
authors.forename: Cindy K
authors.initials: CK
authors.lastname: Cook
authors.forename: Edward E
authors.initials: EE
authors.lastname: Philpot
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Prillaman
authors.forename: Lori A
authors.initials: LA
authors.lastname: Witham
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Faris
authors.forename: Kristofer C
authors.initials: KC
authors.lastname: Klein
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Rickard
mesh_terms: D000280:Administration, Inhalation; D000281:Administration, Intranasal; D000293:Adolescent; D000730:Androstadienes / Q000008:administration & dosage*; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D002648:Child; D004311:Double-Blind Method; D005260:Female; D000068298:Fluticasone; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000503:physiopathology*; D008297:Male; D036501:Metered Dose Inhalers; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000503:physiopathology*
chemical_list: D000730:Androstadienes; D018926:Anti-Allergic Agents; D000068298:Fluticasone; D006854:Hydrocortisone